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Effect of Study Design on the Reported Effect of Cardiac
Resynchronization Therapy (CRT) on Quantitative Physiological
Measures: Stratiﬁed Meta-Analysis in Narrow-QRS Heart Failure and
Implications for Planning Future Studies
Richard J. Jabbour, MRCP; Matthew J. Shun-Shin, MRCP; Judith A. Finegold, MA, MRCP; S. M. Afzal Sohaib, MRCP;
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Josep Brugada, MD; Darrel P. Francis, MA, MD, FRCP
Background-—Biventricular pacing (CRT) shows clear beneﬁts in heart failure with wide QRS, but results in narrow QRS have
appeared conﬂicting. We tested the hypothesis that study design might have inﬂuenced ﬁndings.
Method and Results-—We identiﬁed all reports of CRT-P/D therapy in subjects with narrow QRS reporting effects on continuous
physiological variables. Twelve studies (2074 patients) met these criteria. Studies were stratiﬁed by presence of bias-resistance
steps: the presence of a randomized control arm over a single arm, and blinded outcome measurement. Change in each endpoint
was quantiﬁed using a standardized effect size (Cohen’s d). We conducted separate meta-analyses for each variable in turn,
stratiﬁed by trial quality. In non-randomized, non-blinded studies, the majority of variables (10 of 12, 83%) showed signiﬁcant
improvement, ranging from a standardized mean effect size of +1.57 (95%CI +0.43 to +2.7) for ejection fraction to +2.87 (+1.78 to
+3.95) for NYHA class. In the randomized, non-blinded study, only 3 out of 6 variables (50%) showed improvement. For the
randomized blinded studies, 0 out of 9 variables (0%) showed beneﬁt, ranging from 0.04 (0.31 to +0.22) for ejection fraction to
0.1 (0.73 to +0.53) for 6-minute walk test.
Conclusions-—Differences in degrees of resistance to bias, rather than choice of endpoint, explain the variation between studies of
CRT in narrow-QRS heart failure addressing physiological variables. When bias-resistance features are implemented, it becomes
clear that these patients do not improve in any tested physiological variable. Guidance from studies without careful planning to
resist bias may be far less useful than commonly perceived. ( J Am Heart Assoc. 2015;4:e000896 doi: 10.1161/
JAHA.114.000896)
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C ardiac resynchronization therapy (CRT) undoubtedlyprovides both symptomatic and prognostic beneﬁt in
patients with heart failure and a wide QRS complex.1–3
Whether it is effective in patients with narrow QRS complexes
has appeared contentious. Studies addressing this have
implemented bias-resistance steps (such as the inclusion of
a randomized control arm and blinding of endpoint assess-
ment) to varying degrees, and have addressed a variety of
endpoints. While these studies have been reviewed in the
past, no meta-analysis has focused on trial design as a
potential explanatory variable for the differing results.4
We formally assessed the effect of CRT in patients with
narrow QRS, to identify whether the conﬂict between different
study results was an effect of trial design. To make it possible
to compare effects on different endpoints, we calculated for
each the standardized effect size (Cohen’s d).
Methods
Eligibility and Search Strategy
We identiﬁed all reports of studies of heart failure patients
with narrow QRS (<130 ms) and had either CRT pacemaker
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or CRT deﬁbrillator implantation (CRT-P or CRT-D) inserted.
MEDLINE (1946–September 2013), EMBASE (1974–Septem-
ber 2013), the Cochrane central register of controlled trials
(Cochrane Library 2011, Issue 4), and www.controlled-
trials.com (a meta-registry of randomized controlled clinical
trials that includes the ISRCTN register) were searched
using appropriate terms in the online appendix. Reference
lists of the retrieved articles were hand-searched for
additional publications. Conference presentations of the
reported trials were used if they provided incremental
information.
Effect Sizes
The primary aim of this meta-analysis was to assess
whether bias-resistance elements of study design affect
study results. For each study we included all reported
measured variables of functional status provided on a
continuous scale and common left ventricular function
measurements. For randomized controlled trials we deﬁned
the effect size as the difference between the change scores
in each arm. For single arm studies we deﬁned the effect
size as the reported change score in the intervention arm.
To allow measurements of different physiological quantities
to be compared on a common scale we calculated for each
the standardized effect size (Cohen’s d) by dividing by the
standard deviation of that variable in the patients before
CRT implantation.
Classiﬁcation of Studies by Presence of
Bias-Resistance Features
We stratiﬁed the studies into 3 broad groups depending on
the number of bias-resistance features:
 0 bias-resistance features (Neither an equivalent control
group nor blinding of measurements);
 1 bias-resistance feature (Randomization to a control group
or intervention, but without blinding of patient and
echocardiographic operator);
 2 bias-resistance features (Randomization with blinding of
patient and echocardiographic operator).
The bias-resistance features were only considered valid if
the results presented used them. For example, if a study had a
randomized control arm but only presented data from the
intervention arm then we were obliged to consider the report
to be of a single arm study.
We further assessed all studies using the Cochrane “risk
of bias” tool to qualitatively identify if there were any
additional sources of biases that could have affected the
results.
Data Abstraction
Data was abstracted in duplicate by 2 authors (RJ and CC).
Disagreements were resolved by a third author (MJS).
Data Analysis
We summarized the data and tested for inequality between
the groups using a random-effects meta-analysis using the
statistical environment “R” with the “metafor” package.5 We
stratiﬁed by trial quality along with end-point. Data were
graphically presented using the package “ggplot2.”6
Results
Search Results and Classiﬁcation of Studies by
Bias-Resistance of Design
Three hundred eighty-two articles met the initial search criteria,
of which 131 were duplicates and 51 were excluded at the
abstract stage. From 136 full-text articles screened, 12 studies
(2074 patients) met the inclusion criteria (Figure 1).7–18 Of
these 12 studies, 9 enrolled patients with QRS durations
<120 ms,7–10,12,13,15,16,18 and 3 enrolled patients with QRS
<130 ms.11,14,17 The characteristics and classiﬁcation of
studies are presented in Table 1.
Across the 12 studies, various echocardiographic left
ventricular functional and size parameters, and functional
measured physiological variables were reported including:
ejection fraction, end systolic volume, end diastolic volume,
end systolic diameter, end diastolic diameter, sub-maximal
exercise duration, quality of life score, NYHA class change,
6-minute walk distance, myocardial performance index, peak
VO2, and peak VE/VO2 slope [Table 2].
Figure 1. PRISMA ﬂow diagram of studies
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Classiﬁcation of Studies by Bias-Resistance
Features
Eight studies, including 435 patients, had neither a rando-
mized controlled arm nor blinding.7,9,10,13–16,18 Three of these
were single armed studies.7,13,14 In four of these studies
comparison data was presented, but arose from patients with
a QRS above the threshold and so were analysed as single
armed.9,15,16,18 One of these studies was carried out as a
randomized trial, but only presented continuous variable data
from the intervention arm, and hence was analysed as a single
armed study.10
One study had a randomized control arm but neither
patients nor echocardiographers were blinded to whether CRT
was active, enrolling 60 patients.8
Three studies had both a randomized control arm and
blinding of patients and sonographers totaling 1066 patients.
In these trials the patients received a CRT-D device, with the
control patients having the CRT function inactive.11,12,17
The baseline characteristics and effects of CRT in the
intervention arm are available in Table 3 and the Cochrane
risk of bias assessment tool in Table 4.
Is it Bias-Resistance of Study Design or Choice
of End-Point That Leads to Unintentionally
False-Positive Results?
A series of meta-analyses, one for each end-point, stratiﬁed
by the presence of bias-resistance features, is shown in
Figure 2.
The green diamonds show the meta-analysis summary
results of the randomized, blinded studies. None (0/9, 0%) of
these showed a signiﬁcant effect of CRT on its end-point.
However, the trials with fewer bias-resistance features
showed a different pattern.
The orange diamonds show the results of the randomized,
unblinded study. Half (3/6, 50%) of the end-points showed
statistically signiﬁcant improvement.
The red diamonds show the meta-analysis summary results
of the studies with neither a randomized controlled arm nor
blinding. Most (10/12, 83%) end-points showed statistically
signiﬁcant improvement.
Danger of Viewing Multiple Positive End-Points in
a Trial as Strong Evidence
Commentators sometimes remark on the multiplicity of
positive end-points within a single arm study as though
their great number might somehow overcome the weakness
of the study in lacking blinding, or even lacking a control
arm. This is not wise because this counts the same
patients on multiple occasions as though they were
separate.19
Figure 3 illustrates this danger of viewing multiple positive
endpoints as strong evidence. It shows 1 point for each
endpoint reported in each of the studies. The number of patients
(and bias-resistance of the design) is given by the horizontal
position, and the apparent standardized effect size is given by
the vertical position. The left-hand group of studies, with only a
single arm, and therefore the least bias-resistance, give the
Table 2. Continuous Variables Analysed in Meta-Analysis
Outcome Analyzed
Clinical Echocardiographic
ECHO-CRT11 QOL
LESSER-EARTH12 6MWT, Sub Ex EF, ESV
RethinQ17 6MWT, Peak VO2, QOL EF, EDD, ESD, EDV, ESV
NARROW-CRT10 EF, EDD, ESD, EDV, ESV
RESPOND8 6MWT, NYHA, QOL EF, EDV, ESV
Achilli et al16 6MWT, NYHA EF, EDD, ESD
Bleeker et al18 6MWT, NYHA, QOL EF, EDV, ESV
ESTEEM-CRT7 Peak VO2, VE/VCO2, QOL EF, EDD, ESD, EDV, ESV
Gasparini et al9 6MWT EF, ESV
PROSPECT14 6MWT, NYHA, QOL EF, EDD, ESD, EDV, ESV, MPI
van Bommel13 EF, EDV, ESV
Yu et al15 6MWT, NYHA, QOL, Ex EF, EDD, ESD, EDV, ESV, MPI
EDD indicates left ventricular end diastolic diameter; EDV, left ventricular end diastolic volume; EF, ejection fraction; ESD, left ventricular end systolic diameter; ESV, left ventricular end
systolic volume; Ex, exercise capacity, metabolic equivalent; MPI, myocardial performance index; NYHA, NYHA class change; QOL, quality of life questionnaire; Sub Ex, exercise duration at
submaximal level; VE/VCO2, VE/VCO2 slope.
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-2 0 2 4 6 8
Standardized Mean Difference
6 minute walk time
0.82 [ 0.39 , 1.26 ]Non-randomized, non-blinded
1.14 [ 0.59 , 1.68 ]Randomized, non-blinded
-0.10 [ -0.73 , 0.53 ]Randomized, blinded
Ejection fraction
1.57 [ 0.43 , 2.70 ]Non-randomized, non-blinded
0.14 [ -0.36 , 0.65 ]Randomized, non-blinded
-0.04 [ -0.31 , 0.22 ]Randomized, blinded
Quality of life
0.83 [ 0.60 , 1.07 ]Non-randomized, non-blinded
0.54 [ 0.03 , 1.06 ]Randomized, non-blinded
-0.04 [ -0.17 , 0.08 ]Randomized, blinded
End-systolic volume
0.62 [ 0.04 , 1.19 ]Non-randomized, non-blinded
0.19 [ -0.32 , 0.70 ]Randomized, non-blinded
0.08 [ -0.17 , 0.32 ]Randomized, blinded
End-diastolic volume
0.18 [ 0.05 , 0.32 ]Non-randomized, non-blinded
0.12 [ -0.39 , 0.62 ]Randomized, non-blinded
0.07 [ -0.23 , 0.36 ]Randomized, blinded
Peak VO2
0.06 [ -0.17 , 0.30 ]Non-randomized, non-blinded
Randomized, non-blinded No data
-0.03 [ -0.32 , 0.27 ]Randomized, blinded
End-diastolic diameter
0.35 [ 0.22 , 0.49 ]Non-randomized, non-blinded
Randomized, non-blinded No data
-0.11 [ -0.41 , 0.19 ]Randomized, blinded
End-systolic diameter
0.41 [ 0.13 , 0.70 ]Non-randomized, non-blinded
Randomized, non-blinded No data
0.11 [ -0.19 , 0.41 ]Randomized, blinded
NYHA
2.87 [ 1.78 , 3.95 ]Non-randomized, non-blinded
2.82 [ 2.11 , 3.54 ]Randomized, non-blinded
Randomized, blinded No data
VE/VCO2
-0.03 [ -0.26 , 0.21 ]Non-randomized, non-blinded
Randomized, non-blinded No data
Randomized, blinded No data
Exercise Capacity
0.82 [ 0.50 , 1.14 ]Non-randomized, non-blinded
Randomized, non-blinded No data
Randomized, blinded No data
Myocardial performance index
0.65 [ 0.42 , 0.88 ]Non-randomized, non-blinded
Randomized, non-blinded No data
Randomized, blinded No data
Exercise duration at submaximal level
Non-randomized, non-blinded No data
Randomized, non-blinded No data
-0.25 [ -0.68 , 0.17 ]Randomized, blinded
Mean Difference [95% CI]
Favours intervention
Figure 2. Meta-analyses of effects on physiological variables, with studies stratiﬁed by
number of bias-resistance features in the study design. For each variable a meta-analysis
was conducted stratiﬁed by the presence of bias-resistance features. The majority (10 out
of 12) of variables reported in studies without randomization and blinding (red symbols)
favored intervention to a statistically signiﬁcant degree. In contrast, all 9 of the outcome
variables reported by randomized, blinded trials (green symbols) were neutral. The 6
variables reported by studies with randomization but not blinding (orange symbols) were
equally divided between suggesting signiﬁcant response to intervention (3 variables) and
not (3 variables).
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impression of efﬁcacy. The right-hand group of studies, which
have randomization and blinding, do not.
The key factor is the bias-resistance of the study design,
rather than the choice or number of endpoints.
Discussion
The conﬂict between study reports on the efﬁcacy of
biventricular pacing (CRT) on physiological variables in heart
failure with narrow QRS, seems to originate not in the choice
of physiological endpoint, but in the design of the study. There
may have been unintentional bias introduced when study
design did not possess bias-resistance features. Measure-
ments made for routine clinical purposes do not have the
correct properties for drawing reliable scientiﬁc inferences.
Readers may not realize that such data are not equivalent to
data from a scientiﬁc experiment carefully designed to answer
a question reliably.
In the 3 studies implementing both a randomized control
arm and blinding, the effect of CRT on endpoints is neutral on
these physiological variables. Two of these trials stopped
early due to futility because of detrimental signals in event
rates.11,12
Rationale for CRT Implantation in Relation to QRS
Complex Width
Broad QRS complexes were the deﬁning characteristic of the
early patients receiving CRT from the very ﬁrst case reports
through to the pivotal physiological studies and landmark
trials.2,20–23 The powerful symptomatic and morbidity/mor-
tality reduction were a strong stimulus for attempting
expansion into patients with narrow QRS.3,24
One rationale for such expansion has been the umbrella
concept of dyssynchrony. It was conjectured that CRT might,
even in the absence of electrical dyssynchrony (wide QRS),
alleviate isolated mechanical (echocardiographic) dyssyn-
chrony. More recently however, it has emerged that the
apparent predictive power of mechanical (echocardiographic)
dyssynchrony for beneﬁt from CRT exists only when studies
Figure 3. Effect on physiological-variable endpoints of bias-resistance features and sample size. It is not
statistically valid to “merge” multiple endpoints from the same study as though they are independent.
Unfortunately, however, it is common practice when commenting on a study to highlight that multiple
endpoints are showing a consistent indication. This plot illustrates why such presentation is invalid. Each study
is represented by a series of points, one for each reported endpoint. The horizontal position represents the
bias-resistance group and the sample size (and is therefore is common for all end-points for a single study). As
can be seen, the less bias resistant the design, the greater the tendency to a positive result.
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do not have formal enrollment and blinding of measure-
ments.25
Our ﬁndings are concordant with a recent large meta-
analysis of RCTs of CRT, which showed through a spline-based
regression analysis a direct relationship between QRS width
and prognostic beneﬁt from CRT, with no statistically
signiﬁcant beneﬁt from CRT once the QRS duration falls
below approximately 130 ms.1
Implications for Research
Highlighting the importance of bias-resistance steps such
as randomization and blinding is not novel, having been
introduced in 1948 with Hill’s randomized trial of streptomy-
cin in tuberculosis.26 The published reports of observational,
and incompletely blinded, studies of therapy produce effect
estimates that tend to show exaggerated beneﬁts, and can
even be in the opposite direction to thoroughly blinded,
randomized controlled trials.27 Nevertheless, uncontrolled,
non-randomized, and unblinded routine clinical data are
widely available in every hospital and it is inevitable that
such data will enter the literature. Selective enthusiasm to
report (and review favorably, and publish) positive data,
together called “publication bias,” can further distort the
literature towards positivity, unhelpfully.
Study Limitation?
The lesson to learn may be that lack of a suitable control arm
with randomization and blinding in a study of treatment
outcomes reporting measurements acquired through routine
clinical practice should not be considered merely a minor
“study limitation.” The potential for this bias is so large that a
published study in this class cannot be trusted to give even
approximate guidance.
Rarely are readers explicitly warned that the measurement
(and its associated conﬁdence interval) from non-bias-resis-
tant studies can be so misleading as to get the direction of
effect completely backwards. Table 5 lists, for each study
lacking bias resistance steps, where the study remarks on the
potential for the effect size to be biased and what it says on
the subject.
Table 4. Cochrane Risk of Bias Assessment Tool
Study Adequate Sequence Generation
Allocation
Concealment Blinding Incomplete Outcome Data Free of Selective Reporting
ECHO CRT11 Computer generated randomization Yes Double
Blind
Intentional to treat analysis;
low discontinuation
Yes
LESSER-
EARTH12
Randomized, no further details Yes Double
Blind
Intentional to treat analysis;
low discontinuation
Yes
RethinQ17 Computer generated randomization Yes Double
Blind
Intentional to treat analysis;
low discontinuation
Yes
NARROW-
CRT10
Block randomization; Delivered by sealed envelope
technique
Insufficient
detail
Patients
blinded
Insufficient details Only echocardiographic
parameters from CRT
arm presented
RESPOND8 Computer generated randomization; Delivered by
sealed envelope technique
Insufficient
detail
Unblinded Intentional to treat analysis;
low discontinuation
Yes
Achilli
et al16
Effectively single arm with non-comparable wide
QRS group
Open label Unblinded Insufficient details Yes
Bleeker
et al18
Effectively single arm with non-comparable control
group
Open label Unblinded Insufficient details Yes
ESTEEM-
CRT7
Single Arm Not
applicable
Unblinded Insufficient details Yes
PROSPECT14 Single Arm Not
applicable
Unblinded Insufficient details Yes
Gasparini
et al9
Effectively single arm with non-comparable wide
QRS group
Open label Unblinded Insufficient details Yes
van
Bommel13
Single Arm Not
applicable
Unblinded Insufficient details Yes
Yu et al15 Effectively single arm with non-comparable wide
QRS group
Open label Unblinded Insufficient details Yes
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The weakness of lack of bias-resistance is far worse than
the weakness of small size of RCTs. Small RCTs suffer from
noise, which is an equal tendency to over- or under-estimate
effect sizes. As sample size grows, or as RCTs are synthesized
by meta-analysis, the nature of noise is to progressively
subside. Bias, on other hand, is in a consistent direction. Thus
a non-bias-resistant study cannot safely be used to give a
“rough idea” of what a bias-resistant study would ﬁnd. The
roughness of the idea can dominate any genuine effect, and is
easily underestimated by authors and reader alike. Moreover,
the larger the biased study, the more likely its conﬁdence
interval does not contain the true value.
Meta-analysis of the early observational studies used in
our present analysis, when taken in aggregate, point us
towards physiological beneﬁt.4 When the question is restud-
ied with bias removed, we see physiological neutrality
alongside event-based evidence of harm.11,12 This phenom-
enon has also been seen in observational study designs for
balloon pump therapy, which have consistently generated a
wide range of results which, if read superﬁcially, may be
misleading.28
Nevertheless it should not be forgotten that, while the
impact of such noise shrinks with sample size, the effect of
bias does not. In an irony underappreciated by many of us,
bias-vulnerable studies are more likely to be falsely statisti-
cally signiﬁcant if large than small.29
Impact on Publication and Interpretation of
Unblinded Data
This analysis is not a criticism of the conduct of the studies
listed. One had the primary endpoint of mortality and
therefore did not require blinding to measure their primary
endpoint without bias. Instead, our study puts a spotlight on
what might be the consequences of drawing inferences from
data that inevitably become available from studies that are
unblinded or do not have a control arm. The problem is not
unique to any study’s team, but is common to all of us,
perhaps as the result of our inevitable conditioning by normal
clinical practice, where it may be good practice to portray to
patients a favorable picture of their response to intervention,
in order to maximize the overall symptomatic improvement in
that individual (only part of which is directly mediated by the
device).
Our challenge is to build a community understanding that
when addressing mechanistic questions we should not rely on
unblinded clinical data, originally obtained for individ-
ual-patient clinical purposes, to be a suitable bias-resistant
basis for correct evaluation of physiological beneﬁt. In our
analysis, what the non-bias-resistant clinical data gave was
not a feeble and uncertain pointer, but multiple clear,
consistent, and statistically signiﬁcant pointers to beneﬁt,
but when tested in a bias-resistant manner these turned out
to be wrong.
If the magnitude of unintentional bias can be so large, we
should think carefully before reviewing such data as evidence
in a scientiﬁc forum.
Hypothesis Generating?
Uncontrolled, unblinded, non-randomized data are widely
available and often examined for features that might suggest
an RCT of therapeutic intervention. However, although the
sophisticated authors of such an article might fully under-
stand that an observational study is not a recommendation on
which to base therapeutic decisions but a highlighting of an
interesting area to trial, many readers cannot resist making
this intellectual jump.
The particular hypothesis that CRT would be “beneﬁcial in
heart failure with narrow QRS” could have been generated
directly from the hypotheses in the positive trials for wide
QRS, by simply changing one word. Such a method of
generation would have produced the hypothesis:
1. in less time;
2. at less cost;
3. without obscuring the fact that it was a hypothesis, and
4. preserving the clear understanding (from broad-QRS trials)
of how to test it.
Table 5. Analysis of Single Arm Trials and Acknowledgement of Limitations Associated With Them
Abstract Methods Results Conclusion
Achilli et al16 Not mentioned Not mentioned Not mentioned Not mentioned
Bleeker et al18 Not mentioned Not mentioned Not mentioned Not mentioned
ESTEEM-CRT7 Not mentioned Not mentioned Not mentioned Not mentioned
Gasparini et al9 Not mentioned Not mentioned Not mentioned Not mentioned
PROSPECT14 Not mentioned Not mentioned Not mentioned Not mentioned
van Bommel13 Not mentioned Not mentioned Not mentioned Not mentioned
Yu et al15 Not mentioned Not mentioned Not mentioned Not mentioned
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It is a fallacy that unblinded, non-randomized studies are a
useful step before blinded RCTs for assessing treatment
efﬁcacy. In the case of CRT:
1. In broad-QRS heart failure, the data that was not designed
to resist bias suggested positive beneﬁts. The subsequent
blinded, randomized trials indicated beneﬁt.
2. In narrow-QRS heart failure, the data that was not
designed to resist bias suggested positive beneﬁts. The
subsequent blinded, randomized trials indicated harm.
Thus, the appearance of positive beneﬁts in studies not
designed to resist bias, in 1 group predicted genuine
beneﬁt in survival, and in the other group genuine harm to
survival.
Clinical Implications
When practicing clinical medicine we may ﬁnd it difﬁcult to
resist looking at unblinded non-randomized studies especially
when they are numerous or large or both. Nevertheless, we
should remember the many instances in which they have been
seriously misleading.28, 30-32 We should focus on studies that
incorporate vigorous steps to avoid bias, where such studies
exist. Where there are no such studies, we should identify this
and focus our energies on designing and implementing trials
that have these characteristics. They need not be expensive, if
we do not load them with compulsory features beyond
inexpensive online randomization and a simple incontrovert-
ible endpoint such as all-cause mortality. If the endpoint is
a quantitative physiological marker, then expenditure on
measuring this without bias is not a waste of resources, but
a necessity for preventing the entire trial being a waste of
resources.
Study Limitations
Our search strategy might have missed some studies,
although we attempted to be comprehensive. Secondly, we
focused on physiological variables rather than event end-
points.7,10,11,14 This was needed to allow examination of all 3
classes of study, since uncontrolled studies are unable to
state effects on event rates. Thirdly, some data from the
control arm of 1 randomized trial was missing and could not
be obtained from the corresponding author, and therefore this
trial had to be interpreted as a single arm study.10 Finally, we
could only use the variables provided by the authors. This is
valid as long as the authors did not selectively present
variables that showed an improvement; however, this sus-
ceptibility to bias exists for any reader of such reports. In
addition, if this is an explanation for their discrepancy from
the randomized trials then it further underlines the impor-
tance of preferentially using the prospectively speciﬁed
endpoints from blinded randomized controlled trials as
guidance for clinical decision-making.
Conclusion
Patients with heart failure and narrow QRS complexes appear
to show a physiological improvement with CRT, but only in
unblinded studies or those without a randomized control arm.
When blinding and randomization are implemented the CRT
effect on physiological markers is neutral.
This experience of CRT in narrow-QRS heart failure is
a particularly clear illustration of the need throughout
cardiology to take elaborate steps to prevent inadvertent
bias. The standard method of resisting bias is randomization
and blinding. This requires planning and may appear to
increase cost. However, in retrospect it might have been
preferable to try harder at the outset to acquire bias-resistant
data.
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